

بسم الله الرحمن الرحيم



-Call 4000





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعبدا عن الغبار














بالرسالة صفحات لم ترد بالأصل





Serum Interleukin 35 Level in Relation to T Regulatory and T helper 17 Cells Frequency in Chronic Viral Hepatitis C Patients

Thesis

Submitted for partial fulfilment of M.D. degree in Medical Microbiology and Immunology

Presented by

Safaa Sobhy Mahmoud Abo Elnour

Master degree of Medical Microbiology and Immunology Faculty of Medicine -Ain Shams University

Supervised by

Prof. Dr. Sherine Bendary Elsayed

Professor of Medical Microbiology and Immunology Faculty of Medicine - Ain Shams University

Dr. Dina Mohammad Erfan

Assistant Professor of Medical Microbiology and Immunology Faculty of Medicine - Ain Shams University

Dr. Amira Esmail Abdel Hamid

Lecturer of Medical Microbiology and Immunology Faculty of Medicine - Ain Shams University

Dr. Heba Ismail Saad

Lecturer of Tropical Medicine Faculty of Medicine - Ain Shams University

> Faculty of Medicine Ain Shams University

> > 2020



سورة البقرة الآية: ٣٢

Acknowledgment

First and foremost, I feel always indebted to AUAH, the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Sherine Bendary Elsayed**, Professor of Medical Microbiology and Immunology - Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to **Dr. Dina Mohammad Erfan**, Assistant Professor of Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I am deeply thankful to **Dr. Amira Esmail Abdel Hamid,** Lecturer of Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.

I wish to introduce my deep respect and thanks to **Dr. Ibeba Ismail Saad,** Lecturer of Tropical Medicine, Faculty of Medicine, Ain Shams University, for her kindness, supervision and cooperation in this work.

I owe a deep sense of gratitude to **Prof. Dr. Ossama Ashraf Ahmed,** Professor Gastroenterology and hepatology department, Faculty of Medicine, Ain Shams University, for his great effort, remarkable suggestions and keen interest to see this work become to success.

I would like to express my hearty thanks to all my family and friends for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Safaa Sobhy Mahmoud Abo Elnour

Abstract

Interleukin-35 (IL-35), secreted mainly by T-regulatory cells (T-regs), has been considered to have immunosuppressive actions in many autoimmune diseases and tumors. However, information about its role in chronic hepatitis C (CHC) infection is still limited. We aimed to study the role of IL-35 within CHC infection and to assess its correlation with Tregs and T-helper 17 cells (Th-17). Therefore, we measured serum IL-35 concentrations using ELISA assay in 25 normal controls (NCs) and in 30 CHC patients before receiving direct antiviral agents (DAA) treatment and after 3 months of treatment end. T-regs and Th-17 cells frequencies were assessed via flow-cytometry in control group and patients' group before treatment. The results showed that serum IL-35 levels revealed a highly significant increase in CHC patients compared to NCs (P < 0.001). Moreover, IL-35 levels significantly decreased in patients 3 months after treatment end (P =0.02). Both Th-17 and T-regs were significantly increased in patients more than in NCs and a positive correlation was observed between them. However, T-regs/Th-17 ratio did not show significant difference from the ratio in NCs. IL-35 levels were positively correlated with viral load and T-regs frequency, but not with Th-17 frequency. IL-35 levels did not correlate with liver enzymes or functions. These results suggested that IL-35 enhances the immunosuppressive functions of T-regs, protecting the liver from HCV induced damage and contributes to viral persistence. IL-35 may represent a possible immunotherapeutic strategy for chronic persistent infection if given with DAA, especially in relapsing or non-responding cases.

List of Contents

| Title | Page No. |
|------------------------|----------|
| List of Tables | i |
| List of Figures | iii |
| List of Abbreviations | v |
| Introduction | 1 |
| Aim of the Work | 5 |
| Review of Literature | |
| 😂 Hepatitis C Virus | 6 |
| Immune Response to HCV | 50 |
| 📚 Interleukin 35 | 76 |
| Patients and Methods | 83 |
| Results | 99 |
| Discussion | 116 |
| Summary and Conclusion | 137 |
| Recommendations | 143 |
| References | 144 |
| Arabic Summary | 1 |

List of Tables

| Table No. | Title | Page No. |
|--------------------|--|----------------|
| Table (1): | CTP score is obtained by adding to each parameter | |
| Table (2): | Interpretation of HCV serological | test results31 |
| Table (3): | Recent surveys for HCV prevalen | |
| Table (4): | Dilution of standard solutions wa | |
| Table (5): | Demographic data of patients (N= | =30):99 |
| Table (6): | Patients laboratory work up | |
| | treatment and after 3 months of | |
| | end | 100 |
| Table (7): | Comparison between laboratory before treatment and 3 months treatment among patients: | after end of |
| Table (8): | Correlation between viral load (eRT-PCR) and liver enzymes amor | - |
| Table (9): | Serum IL-35 level, T-regs | and Th-17 |
| | percentage among patients: | |
| Table (10): | Serum IL-35 level, T-regs | |
| | percentage among controls | |
| Table (11): | Comparison between patients a regarding Serum IL-35 level, T-percentage and Tregs/Th-17 rati | regs, Th-17 |
| Table (12): | Correlation between serum IL-3 | |
| | regs and Th-17 among patients: | |
| Table (13): | Correlation between IL-35 | and other |
| | laboratory work up | 112 |
| Table (14): | Correlation between T-regs | |
| | frequency and other laboratory w | = |
| Table (1): | Relation between T regs and results | |

List of Tables

| Table No. | | Title | | Page No. |
|-------------------|---------------------|-------|--|------------|
| Table (2): | | | | fibro-scan |
| Table (3): | Correlation results | | | |

List of Figures

| Fig. No. | Title | Page No. |
|---------------------|--|--------------|
| Figure (1): | A model of HCV lipoviral particle | 8 |
| Figure (2): | HCV Model structure and organization, NTR: Non Translated | • |
| Figure (3): | Organization of the HCV genome | 11 |
| Figure (4): | Distribution of HCV Genotypes World | |
| Figure (5): | HCV life cycle | 17 |
| Figure (6): | Course of acute, resolving hepatitic and acute hepatitis C that evolve chronic infection (B) | es into |
| Figure (7): | Natural history following infection hepatitis C virus | on with |
| Figure (8): | Schematic representation of the immune response during acute infection | e HCV |
| Figure (9): | Suppressive functions of T-reinhibitory cytokines | egs by |
| Figure (10): | Suppressive functions of T-regs by c | |
| Figure (11): | Suppressive functions of T-remetabolic disruption | egs by |
| Figure (12): | Suppressive functions of T-regs maturation or function | by DC |
| Figure (13): | CD4 T cell differentiation | 69 |
| Figure (14): | Transcriptional regulation of Tidifferentiation | |
| Figure (15): | Biological Effects of Th17 cells | |
| Figure (16): | IL-35 and IL-35 R structure | 77 |
| Figure (17): | IL35 dependant signalling pathway | 7. 78 |
| Figure (18): | Biologic functions of IL-35 on immune | |
| Figure (19): | As regard IL35 functional roles in di | sease 81 |

List of Figures (Cont...)

| Fig. No. | Title | Page No. |
|---------------------|--|----------|
| Figure (20): | Hydrodynamic focusing produces stream of particles | |
| Figure (21): | Electrostatic flow sorting | 89 |
| Figure (22): | Lymphocytes stained with anti-CD anti-CD25 PE and anti CD127 PC5: | , |
| Figure (23): | Lymphocytes stained with anti C CD4 PC5 and anti IL-17A FITC: | • |
| Figure (24): | Standard dilutions preparation | 96 |
| Figure (25): | Fibro-scan results in patients | 101 |
| Figure (26): | Comparison between patients and regarding IL-35 serum level (ng/ml). | |
| Figure (27): | Comparison between patients and regarding Tregs frequency (%) | controls |
| Figure (28): | Comparison between patients and regarding Th-17 frequency (%) | |
| Figure (29): | Comparison between serum IL-3 before treatment and 3 months after | 35 level |
| | treatment among patients | 109 |
| Figure (30): | Scatter plot for correlation between (%) and TH 17 (%) | _ |

List of Abbreviations

| Abb. | Full term |
|--------------|---|
| AASLD | American Association for the Study of Liver Diseases |
| <i>AFP</i> | Serum alpha fetoprotein |
| <i>ALT</i> | Alanine transferase |
| anti-HCV | Antibodies to hepatitis C |
| <i>AST</i> | Aspartate aminotransferase |
| <i>bDNA</i> | Branched deoxyribonucleic acid |
| <i>C</i> | Core |
| <i>CDC</i> | Control and Prevention |
| cDCs | Conventional DCs |
| <i>CHC</i> | Chronic hepatitis C |
| CTLs | Cytotoxic T cells |
| <i>CTP</i> | Child-Turcotte-Pugh |
| DAA | Direct antiviral agents |
| DCs | Dendritic cells |
| <i>E</i> | Envelope |
| <i>EDHS</i> | Egyptian Demographic Health Survey |
| <i>EHIS</i> | Egyptian Health Issues Survey |
| FDA | Food and Drug Administration |
| <i>HBV</i> | Hepatitis B virus |
| HCC | Hepatocellular carcinoma |
| HCV | Hepatitis C virus |
| <i>IFN</i> | Interferon |
| <i>IL</i> | |
| <i>IL-35</i> | Interleukin 35 |
| <i>ITIM</i> | Inhibition motif–containing |
| <i>KIRs</i> | Killer Inhibitory Receptors |
| <i>LFT</i> | Liver function tests |
| <i>MAPK</i> | Mitogen-activated protein kinase |